TL12: Biomarkers for Rare Events
*Samir Lababidi, FDA 

Keywords: Biomarkers, Rare Events, Safety

Assessing safety in clinical trials with rare events can be challenging. With the rich literature of biomarkers over the last several years, how do biomarkers help in improving safety evaluation? What are the key methodological issues in using biomarkers for clinical trials with rare events?